The stock's rise snapped a four-day losing streak.

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Atlas Capital Advisors didn’t just up their Regeneron stake—they launched it into orbit with a 5,620.3% increase, now holding ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Regeneron Pharmaceuticals Inc. closed 49.58% below its 52-week high of $1,211.20, which the company achieved on August 27th.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...